Single-Agent Pembrolizumab (Keytruda) May Benefit Patients with Rare Type of Melanoma; Results Presented at AACR 2023 Annual Meeting

Monotherapy with pembrolizumab (Keytruda) led to clinical responses in 89% of
patients with unresectable metastatic desmoplastic melanoma, according to results from a phase II clinical trial presented (CT009) at American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19 in Orlando, Florida. Desmoplastic melanoma is a rare subtype of melanoma, accounting for approximately 4% of melanoma cases in the United States.